Table 1 Baseline characteristics of the population.
Characteristics | Total (N = 198) | Alive (N = 178) | Dead (N = 20) | P-value |
|---|---|---|---|---|
Mean age, years | 62.4 ± 14.8 | 61.3 ± 14.7 | 72.8 ± 11.8 | < 0.001 |
Gender | 1.000 | |||
Male | 111 (56.1%) | 100 (56.2%) | 11 (55.0%) | |
Female | 87 (43.9%) | 78 (43.9%) | 9 (45.0%) | |
Mean body mass index (kg/m2) | 23.1 ± 4.9 | 23.3 ± 5.2 | 21.4 ± 2.6 | 0.108 |
Smoking status | 0.695 | |||
No smoking | 144 (72.7%) | 130 (73.0%) | 14 (72.7%) | |
Ex-smoker | 41 (20.7%) | 35 (19.7%) | 6 (30.0%) | |
Current smoker | 4 (2%) | 4 (2.2%) | 0 (0%) | |
Comorbidities | ||||
Diabetes mellitus | 89 (44.9%) | 79 (44.4%) | 10 (50.0%) | 0.681 |
Dyslipidemia | 105 (53.0%) | 94 (52.8%) | 11 (55.0%) | 1.000 |
Hypertension | 180 (90.9%) | 161 (90.9%) | 19 (95.0%) | 1.000 |
Atrial fibrillation | 23 (11.7%) | 18 (10.2%) | 5 (25.0%) | 0.065 |
Coronary artery disease | 26 (13.1%) | 23 (12.9%) | 3 (15.0%) | 0.733 |
Cerebrovascular disease | 21 (10.6%) | 19 (10.7%) | 2 (10.0%) | 1.000 |
Chronic obstructive pulmonary disease | 2 (1%) | 1 (0.6%) | 1 (5.0%) | 0.193 |
Medication | ||||
Antiplatelet | 71 (35.9%) | 64 (36.2%) | 7 (35.0%) | 1.000 |
Beta-blockers | 126 (63.6%) | 113 (66.1%) | 13 (65.0%) | 1.000 |
ACEi/ARB | 51 (25.8%) | 41 (23.9%) | 10 (50.0%) | 0.029 |
Calcium channel blockers | 127 (64.1%) | 114 (66.7%) | 13 (65.0%) | 1.000 |
Statins | 112 (56.6%) | 102 (59.6%) | 10 (50.0%) | 0.475 |
Oral anticoagulant | 18 (9.1%) | 12 (7.0%) | 6 (30.0%) | 0.005 |
Dialytic data | ||||
Dialysis vintage (months), median (IQR) | 37.2 (22.4–60.3) | 37.5 (22.9–60.2) | 34.8 (21.9–61.2) | 0.773 |
Dialysis frequency | 1.000 | |||
2 times per week | 11 (5.6%) | 10 (5.6%) | 1 (5.0%) | |
3 times per week | 187 (94.4%) | 168 (94.4%) | 19 (95.0%) | |
Dialysis access | 0.619 | |||
Arteriovenous fistula | 138 (69.7%) | 126 (70.8%) | 12 (63.2%) | |
Arteriovenous graft | 8 (4%) | 7 (3.9%) | 1 (5.3%) | |
Perm catheter | 50 (25.4%) | 44 (24.7%) | 6 (31.6%) | |
Double lumen catheter | 1 (0.6%) | 0 (0.0%) | 1 (0.5%) | |
Laboratory data | ||||
Serum sodium (mEq/L) | 136.7 ± 3.3 | 136.8 ± 3.3 | 135.9 ± 3.4 | 0.210 |
Serum potassium (mEq/L) | 4.4 ± 0.6 | 4.5 ± 0.6 | 4.4 ± 0.6 | 0.526 |
Hemoglobin (g/dL) | 10.4 ± 1.4 | 10.5 ± 1.4 | 9.6 ± 1.1 | 0.027 |
Serum albumin (g/dL) | 4.0 ± 0.4 | 4.0 ± 0.4 | 3.5 ± 0.5 | < 0.001 |
hs-cTnI (ng/L), median (IQR) | 18.4 (9.5–36.6) | 17.2 (9.4–33.4) | 27.3 (13.3–43.4) | 0.105 |
≥ 26.2 ng/L | 68 (34.3%) | 58 (32.6%) | 10 (50%) | 0.139 |
hs-cTnT (ng/L), median (IQR) | 61.1 (36.6–102.0) | 59.0 (36.0–95.8) | 111.4 (56.4–174.1) | 0.002 |
≥ 14 ng/L | 196 (99%) | 176 (98.9%) | 20 (100.0%) | 1.000 |
